Page 2 - Amanda Sheldon News Today

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone payments (totaling $40 million), as well as tiered, double-digit royaltiesAgreement offers pathway to potentially offering a novel non-steroidal topical option to the millions of Japanese patients suffering from inflammatory skin diseases WESTLAKE VILLAGE, Calif. and TOKYO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage bi

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone payments (totaling $40...

Q4 net product revenues for ZORYVE® cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven by...

WESTLAKE VILLAGE, Calif., Jan. 31, 2024 -- Arcutis Biotherapeutics, Inc. , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today...

Novel steroid-free topical foam effectively controls seborrheic dermatitisOnce-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older

First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this weekEffective, safe, and very well-tolerated steroid-free foam provides...

Arcutis today announced new individual patient response data in Atopic Dermatitis with roflumilast cream according to new data from Phase 3 program...

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index in just 4 weeks85% achieved measurable...

Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by...

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 -- Arcutis Biotherapeutics, Inc. , an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the...